31 biopharmaceutical companies are now involved in the research and development of psychedelic compounds to treat mental health issues such as obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, depression, anxiety, and eating disorders. This article tracks the performance of 15 of them in the munKNEE Psychedelic Stocks Index.

Index Inclusion Criteria

The 15 stocks eligible for inclusion in the index are based on the following criteria:

• a market capitalization between US$10M and US$200M
• a stock that trades between US$0.10/share and US$2/share

Below are the 15 eligible companies in the munKNEE Psychedelic Stocks Index and their performance on Thursday, December 17th in descending order. Yesterday's performance for each is in brackets.

1. Champignon (SHRMF) +10.6% (-6.8%)  
2. Hollister (HSTRF) +8.2% (-17.9%) 
3. Numinus (LKYSF) +5.2% (-7.3%) 
4. Mydecine (MYCOF) +5.2% (-7.3%) 
5. Mind Cure (MCURF) +5.2% (-12.7%) 
6. Seelos (SEEL) +4.9% (+6.8%) 
7. Psyched Wellness (DCNPF) +4.0% (-11.7%) 
8. Red Light (TRUFF) +3.5% (-10.8%)
9. Silo Pharma (SILO) +3.3% (+2.3%) 
10. Cybin (CLXPF) +1.6% (+5.7%)
11. Nova Mentis (LIBFF) N/C (-11.1%) 
12. Revive (RVVTF) N/C (+3.2%) 
13. Havn (HAVLF) -1.5% (+8.5%)
14. Better Plant (VEGGF) -8.4% (-7.3%) 
15. Jaguar (JAGX) -16.3% (+5.8%)

The average performance of the above 15 psychedelic drug stocks on Thursday was +2.7% vs. +9.3% on Wednesday, -15.9% on Tuesday and +27.2% on Monday. Interestingly, in comparison, the munKNEE Pure-Play Pot Stock Index of the 25 pure-play cannabis stocks that trade in excess of US$1/share was -0.3% on Thursday compared to +2.6% on Wednesday, +2.2% on Tuesday and -2.3% on Monday. To avoid duplication please refer to a previous article (see here) in which I provided introductory paragraphs on each of the above constituents.

NOTE: The 3 largest psychedelic drug stocks in the sector were, on average, up 0.6% on Thursday compared to +1.1% on Wednesday,  -1.0% on Tuesday, and  -2.0% on Monday. They are not included in the Index because they either trade in excess of $2/share and/or have a market cap in excess of $200M because their inclusions would make a comparative analysis and Index averages meaningless. For the record, below are their  performances with  their performances for yesterday in brackets:

1. MindMed (MMEDF) +8.9% (-6.8%) 
2. Compass (CMPS) +0.5% (+2.2%)
3. Field Trip (FTRPF) -4.6% (-7.1%)

The remaining 13 stocks in this fledgling, yet burgeoning, sector were unchanged, on average, on Thursday. They are not eligible for inclusion in the munKNEE Psychedelic Stocks Index but are worth watching closely (see a previous article on the subject here) with the sector starting to gain considerable traction. They are as follows:

• Aion (AION), Codebase (BKLLF), Ehave (EHVVF), Graph Blockchain (REGRF), Lobe Sciences (GTSIF),  Minerco (MINE), New Wave (TRMNF), Thoughtful Brands (PEMTF), Entheon (ENBI), Core One (CLABF), Newscope-PharmaTher (PHRM) and Nutritional High (SPLIF) and Pure Extracts (PULL).

In sum total, the entire 31 stocks were up 0.8% Thursday on top of +1.9% on Wednesday.